Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from Minnesota
Based on 227 articles published since 2008
||||

These are the 227 published articles about Parkinson Disease that originated from Minnesota during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10
1 Editorial Take care to identify apathy in idiopathic rapid eye movement sleep behavior disorder. 2018

St Louis, E K. ·Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. ·Eur J Neurol · Pubmed #29528541.

ABSTRACT: -- No abstract --

2 Editorial The future burden of Parkinson's disease. 2018

Rocca, Walter A. ·Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. · Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. ·Mov Disord · Pubmed #28782890.

ABSTRACT: -- No abstract --

3 Editorial Understanding Parkinson disease in sub Saharan Africa: A call to action for the international neurologic community. 2017

Bower, James H. ·Department of Neurology, Mayo Clinic, Rochester, MN, USA. ·Parkinsonism Relat Disord · Pubmed #28528803.

ABSTRACT: -- No abstract --

4 Editorial Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up. 2017

Boylan, Laura S / Messinis, Lambros. ·From the Department of Neurology (L.S.B.), New York University School of Medicine, New York · Department of Neurology (L.S.B.), Essentia Health, Duluth, MN · Department of Neurology (L.S.B.), Bellevue Hospital, New York, NY · and Neuropsychology Section, Department of Neurology (L.M.), University of Patras Medical School, Greece. ·Neurology · Pubmed #27903812.

ABSTRACT: -- No abstract --

5 Editorial MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease? 2015

Öz, Gülin. ·Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA. ·Mov Disord · Pubmed #26184363.

ABSTRACT: -- No abstract --

6 Editorial A 'bird's eye' view on the current status and potential benefits of blood biomarkers for Parkinson's disease. 2014

Mielke, Michelle M / Maetzler, Walter. ·Departments of Health Sciences Research & Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. ·Biomark Med · Pubmed #24521018.

ABSTRACT: -- No abstract --

7 Editorial Is rapid eye movement sleep behavior disorder in Parkinson disease a specific disease subtype? 2013

McCarter, Stuart J / St Louis, Erik K / Boeve, Bradley F. ·Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic and Foundation, Rochester, MN, United States. ·Sleep Med · Pubmed #23993870.

ABSTRACT: -- No abstract --

8 Review Thermoregulation in Parkinson disease. 2018

Coon, Elizabeth A / Low, Phillip A. ·Department of Neurology, Mayo Clinic, Rochester, MN, United States. Electronic address: coon.elizabeth@mayo.edu. · Department of Neurology, Mayo Clinic, Rochester, MN, United States. ·Handb Clin Neurol · Pubmed #30459035.

ABSTRACT: Autonomic dysfunction in Parkinson disease encompasses thermoregulatory symptoms and was first noted by Gowers in the late 19th century when he described abnormal temperature sensation and sweating in Parkinson disease patients. These thermoregulatory symptoms became more recognized in the postlevodopa era when Parkinson disease patients were more readily tested with objective autonomic function tests. Objective thermoregulatory testing in Parkinson disease reveals deficits of sweating and vasomotor tone which often correlate with the severity of other autonomic deficits. Tests of thermoregulatory function can also be used to differentiate Parkinson disease from other neurodegenerative disorders. The pathophysiology of thermoregulatory dysfunction in Parkinson disease encompasses both central and peripheral mechanisms; involvement of the brainstem and hypothalamus with alpha-synuclein pathology is well recognized with increasing evidence of peripheral neuropathy in Parkinson disease that influences thermoregulation. Medications used to treat Parkinson disease also affect thermoregulatory symptoms. Disorders of thermoregulation significantly affect the quality of life for patients and their caregivers and can be severe and even life threatening, such as in the parkinsonism-hyperpyrexia syndrome.

9 Review The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. 2018

Ben-Pazi, H / Browne, P / Chan, P / Cubo, E / Guttman, M / Hassan, A / Hatcher-Martin, J / Mari, Z / Moukheiber, E / Okubadejo, N U / Shalash, A / Anonymous1401121. ·Neuropediatric unit, Shaare Zedek Medical Center, Jerusalem, Israel. · Neurology Department, University Hospital Galway, Newcastle Road, Galway, Ireland. · School of Medicine, National University of Ireland Galway, Galway, Ireland. · Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University Beijing, Beijing, China. · Neurology Department, University Hospital, Burgos, Spain. mcubo@saludcastillayleon.es. · University of Toronto, Toronto, ON, Canada. · Department of Neurology, Mayo Clinic, Rochester, MN, USA. · Movement Disorders Program, Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. · Parkinson's Disease and Movement Disorders Program, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA. · Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA. · Neurology Unit, Department of Medicine, College of Medicine, University of Lagos, Lagos State, Nigeria. · Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ·Curr Neurol Neurosci Rep · Pubmed #29654523.

ABSTRACT: PURPOSE OF REVIEW: Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs. RECENT FINDINGS: Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research. Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.

10 Review Aerobic Exercise: Evidence for a Direct Brain Effect to Slow Parkinson Disease Progression. 2018

Ahlskog, J Eric. ·Department of Neurology, Mayo Clinic, Rochester, MN. Electronic address: eahlskog@Mayo.edu. ·Mayo Clin Proc · Pubmed #29502566.

ABSTRACT: No medications are proven to slow the progression of Parkinson disease (PD). Of special concern with longer-standing PD is cognitive decline, as well as motor symptoms unresponsive to dopamine replacement therapy. Not fully recognized is the substantial accumulating evidence that long-term aerobic exercise may attenuate PD progression. Randomized controlled trial proof will not be forthcoming due to many complicating methodological factors. However, extensive and diverse avenues of scientific investigation converge to argue that aerobic exercise and cardiovascular fitness directly influence cerebral mechanisms mediating PD progression. To objectively assess the evidence for a PD exercise benefit, a comprehensive PubMed literature search was conducted, with an unbiased focus on exercise influences on parkinsonism, cognition, brain structure, and brain function. This aggregate literature provides a compelling argument for regular aerobic-type exercise and cardiovascular fitness attenuating PD progression.

11 Review Microbiome, Immunomodulation, and the Neuronal System. 2018

Marietta, Eric / Horwath, Irina / Taneja, Veena. ·Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. · Department of Immunology, Mayo Clinic, Rochester, MN, USA. · Department of Immunology, Mayo Clinic, Rochester, MN, USA. taneja.veena@mayo.edu. · Division of Rheumatology, Mayo Clinic, Rochester, MN, USA. taneja.veena@mayo.edu. ·Neurotherapeutics · Pubmed #29313275.

ABSTRACT: Vertebrates harbor both symbiotic and pathogenic bacteria on the body and various mucosal surfaces. Of these surfaces, the intestine has the most diverse composition. This composition is dependent upon various environmental and genetic factors, with diet exerting the maximum influence. Significant roles of the intestinal bacteria are to stimulate the development of a competent mucosal immune system and to maintain tolerance within the intestine. One manner in which this is achieved is by the establishment of epithelial integrity by microbiota found in healthy individuals (healthy microbiota); however, in the case of a disrupted intestinal microbiome (dysbiosis), which can be caused by various conditions, the epithelial integrity is compromised. This decreased epithelial integrity can then lead to luminal products crossing the barrier, generating a systemic proinflammatory response. In addition to epithelial integrity, healthy intestinal commensals metabolize indigestible dietary substrates and produce short-chain fatty acids, which are bacterial metabolites that are essential for colonic health and regulating the function of the intestinal immune system. Intestinal commensals are also capable of producing neuroactive molecules and neurotransmitters that can affect the function of the vagus nerve. The observations that intestinal dysbiosis is associated with different diseases of the nervous system, suggests that cross-talk occurs amongst the gut, the nervous system, and the immune system.

12 Review Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis. 2018

Wijarnpreecha, Karn / Chesdachai, Supavit / Jaruvongvanich, Veeravich / Ungprasert, Patompong. ·Department of Internal Medicine, Bassett Medical Center, Cooperstown, New York. · Department of Medicine, Faculty of Medicine Ramathibodi Hospital. · Department of Internal Medicine, University of Hawaii, Honolulu, Hawaii. · Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA. · Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. ·Eur J Gastroenterol Hepatol · Pubmed #29049127.

ABSTRACT: BACKGROUND/OBJECTIVE: Hepatitis C virus (HCV) infection is one of the most common infections worldwide. Recent epidemiologic studies have suggested that patients with HCV infection might be at an increased risk of Parkinson's disease. However, the data on this relationship remain inconclusive. This meta-analysis was conducted with the aim to summarize all available evidence. PATIENTS AND METHODS: A literature search was performed using MEDLINE and EMBASE database from inception to May 2017. Studies that reported relative risks, odd ratios (ORs), or hazard ratios comparing the risk of Parkinson's disease among HCV-infected patients versus participants without HCV infection were included. Pooled OR and 95% confidence interval were calculated using a random-effect, generic inverse variance method. RESULTS: Of 468 studies, five studies with 323 974 participants met our eligibility criteria and were included in the analysis. We found a higher risk of Parkinson's disease among patients with chronic HCV infection compared with participants without HCV infection with the pooled OR of 1.35 (95% confidence interval: 1.19-1.52). The statistical heterogeneity of this study was insignificant (I=3%). The main limitation of this meta-analysis was the limited accuracy of diagnosis in the primary studies as they were coding-based studies. CONCLUSION: This study demonstrated a higher risk of Parkinson's disease among HCV-infected patients. Further studies are required to clarify how this risk should be addressed in the clinical picture.

13 Review Locus coeruleus. 2018

Benarroch, Eduardo E. ·Department of Neurology, Mayo Clinic, 200 First Street SW (Southwest), Rochester, MN, 55905, USA. Benarroch.eduardo@mayo.edu. ·Cell Tissue Res · Pubmed #28687925.

ABSTRACT: The locus coeruleus (LC) contains norepinephrine (NE)-synthesizing neurons that send diffuse projections throughout the central nervous system. The LC-NE system has a major role in arousal, attention and stress responses. In the brain, NE may also contribute to long-term synaptic plasticity, pain modulation, motor control, energy homeostasis and control of local blood flow. The LC is severely affected in neurodegenerative disorders including Parkinson disease (PD). Involvement of the noradrenergic neurons of the LC precedes that of dopaminergic neurons of the substantia nigra pars compacta and has been increasingly recognized as a potential major contributor to cognitive manifestations in early PD, particularly impaired attention. Abnormal noradrenergic signaling may also potentially contribute to motor manifestations of the disease.This makes the LC-NE system a major contributor to the pathobiology and potential target for therapy of PD.

14 Review Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. 2017

Fields, Julie A. ·Division of Neurocognitive Disorders, Mayo Clinic College of Medicine, Rochester, MN, USA. ·Arch Clin Neuropsychol · Pubmed #28961866.

ABSTRACT: Cognitive impairment and neuropsychiatric symptoms affect a substantial number of individuals with Parkinson's disease (PD). These non-motor changes can occur at all stages of disease, often years before motor symptoms manifest in some patients while occurring much later in the disease process for others. Lewy bodies are the hallmark of PD, yet not all patients with PD follow the same course or present in the same way clinically, either from a motor or non-motor standpoint. This has implications on assessment, intervention, and planning for the future. This review will focus on the cognitive and neuropsychiatric features of Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), with emphasis on neuropsychological findings. Differentiation between these dementia syndromes and other atypical parkinsonian syndromes will be mentioned only briefly, as the latter are covered in detail elsewhere in this issue. Neuropathologic, laboratory and radiographic findings will be presented, and recommendations for neurobehavioral assessment and treatment will be provided.

15 Review Neurostimulation Devices for the Treatment of Neurologic Disorders. 2017

Edwards, Christine A / Kouzani, Abbas / Lee, Kendall H / Ross, Erika K. ·School of Engineering, Deakin University, Geelong, Victoria, Australia; Department of Neurologic Surgery, Mayo Clinic, Rochester, MN. · School of Engineering, Deakin University, Geelong, Victoria, Australia. · Department of Neurologic Surgery, Mayo Clinic, Rochester, MN; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN. · Department of Neurologic Surgery, Mayo Clinic, Rochester, MN; Department of Surgery, Mayo Clinic, Rochester, MN. Electronic address: ross.erika@mayo.edu. ·Mayo Clin Proc · Pubmed #28870357.

ABSTRACT: Rapid advancements in neurostimulation technologies are providing relief to an unprecedented number of patients affected by debilitating neurologic and psychiatric disorders. Neurostimulation therapies include invasive and noninvasive approaches that involve the application of electrical stimulation to drive neural function within a circuit. This review focuses on established invasive electrical stimulation systems used clinically to induce therapeutic neuromodulation of dysfunctional neural circuitry. These implantable neurostimulation systems target specific deep subcortical, cortical, spinal, cranial, and peripheral nerve structures to modulate neuronal activity, providing therapeutic effects for a myriad of neuropsychiatric disorders. Recent advances in neurotechnologies and neuroimaging, along with an increased understanding of neurocircuitry, are factors contributing to the rapid rise in the use of neurostimulation therapies to treat an increasingly wide range of neurologic and psychiatric disorders. Electrical stimulation technologies are evolving after remaining fairly stagnant for the past 30 years, moving toward potential closed-loop therapeutic control systems with the ability to deliver stimulation with higher spatial resolution to provide continuous customized neuromodulation for optimal clinical outcomes. Even so, there is still much to be learned about disease pathogenesis of these neurodegenerative and psychiatric disorders and the latent mechanisms of neurostimulation that provide therapeutic relief. This review provides an overview of the increasingly common stimulation systems, their clinical indications, and enabling technologies.

16 Review REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. 2017

St Louis, Erik K / Boeve, Angelica R / Boeve, Bradley F. ·Center for Sleep Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. · Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. ·Mov Disord · Pubmed #28513079.

ABSTRACT: Rapid eye movement sleep behavior disorder is characterized by dream enactment and complex motor behaviors during rapid eye movement sleep and rapid eye movement sleep atonia loss (rapid eye movement sleep without atonia) during polysomnography. Rapid eye movement sleep behavior disorder may be idiopathic or symptomatic and in both settings is highly associated with synucleinopathy neurodegeneration, especially Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. Rapid eye movement sleep behavior disorder frequently manifests years to decades prior to overt motor, cognitive, or autonomic impairments as the presenting manifestation of synucleinopathy, along with other subtler prodromal "soft" signs of hyposmia, constipation, and orthostatic hypotension. Between 35% and 91.9% of patients initially diagnosed with idiopathic rapid eye movement sleep behavior disorder at a sleep center later develop a defined neurodegenerative disease. Less is known about the long-term prognosis of community-dwelling younger patients, especially women, and rapid eye movement sleep behavior disorder associated with antidepressant medications. Patients with rapid eye movement sleep behavior disorder are frequently prone to sleep-related injuries and should be treated to prevent injury with either melatonin 3-12 mg or clonazepam 0.5-2.0 mg to limit injury potential. Further evidence-based studies about rapid eye movement sleep behavior disorder are greatly needed, both to enable accurate prognostic prediction of end synucleinopathy phenotypes for individual patients and to support the application of symptomatic and neuroprotective therapies. Rapid eye movement sleep behavior disorder as a prodromal synucleinopathy represents a defined time point at which neuroprotective therapies could potentially be applied for the prevention of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. © 2017 International Parkinson and Movement Disorder Society.

17 Review REM sleep behaviour disorder: prodromal and mechanistic insights for Parkinson's disease. 2017

Tekriwal, Anand / Kern, Drew S / Tsai, Jean / Ince, Nuri F / Wu, Jianping / Thompson, John A / Abosch, Aviva. ·Department of Neurosurgery, University of Colorado-Anschutz Medical Center, Denver, Colorado, USA. · Department of Neurology, University of Colorado-Anschutz Medical Center, Denver, Colorado, USA. · Biomedical Engineering, University of Houston, Houston, Texas, USA. · Neuromodulation Global Research, Medtronic, Minneapolis, Minnesota, USA. ·J Neurol Neurosurg Psychiatry · Pubmed #27965397.

ABSTRACT: Rapid eye movement (REM) sleep behaviour disorder (RBD) is characterised by complex motor enactment of dreams and is a potential prodromal marker of Parkinson's disease (PD). Of note, patients with PD observed during RBD episodes exhibit improved motor function, relative to baseline states during wake periods. Here, we review recent epidemiological and mechanistic findings supporting the prodromal value of RBD for PD, incorporating clinical and electrophysiological studies. Explanations for the improved motor function during RBD episodes are evaluated in light of recent publications. In addition, we present preliminary findings describing changes in the activity of the basal ganglia across the sleep-wake cycle that contribute to our understanding of RBD.

18 Review Epidemiology of alpha-synucleinopathies: from Parkinson disease to dementia with Lewy bodies. 2016

Savica, R / Boeve, B F / Logroscino, G. ·Department of Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: Savica.Rodolfo@mayo.edu. · Department of Neurology, Mayo Clinic, Rochester, MN, USA. · Department of Neurology, Mayo Clinic, Rochester, MN, USA; Neurodegenerative Diseases Unit, Department of Basica Medicine, Neuroscience and Sense Organs, University of Bari, Italy. ·Handb Clin Neurol · Pubmed #27637957.

ABSTRACT: The epidemiology of the diagnosis of Parkinson's disease and dementia with Lewy bodies is still based on clinical criteria and the definition of the different diseases is still a challenge for clinician and researcher. The epidemiologic estimates of prevalence and incidence are highly affected by differences in diagnostic criteria, geographic location, and methodologic limitations. Studies of prevalence and incidence show increases with advancing age and a higher rate of Parkinson's disease and dementia with Lewy bodies in men compared to women.

19 Review Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging. 2016

Vemuri, Prashanthi / Fields, Julie / Peter, Jessica / Klöppel, Stefan. ·aDepartment of Radiology bDivision of Neurocognitive Disorders, Mayo Clinic, Rochester, Minnesota, USA cDepartment of Psychiatry and Psychotherapy dCenter for Geriatrics and Gerontology, University Medical Center Freiburg, Freiburg, Germany. ·Curr Opin Neurol · Pubmed #27213773.

ABSTRACT: PURPOSE OF REVIEW: There has been recent debate about the lack of compelling scientific evidence on the efficacy of cognitive interventions. The goal of this study is to review the current state of cognitive interventions in Alzheimer's disease and Parkinson's disease, present emerging mechanisms, and discuss the role of imaging in designing effective intervention strategies. RECENT FINDINGS: Cognitive interventions appear to be promising in Alzheimer's disease and Parkinson's disease. Although feasibility has been shown in mild cognitive impairment, early Alzheimer's disease, and mild to moderate Parkinson's disease, studies to investigate long-term efficacy and mechanisms underlying these interventions are still needed. SUMMARY: There is a need to conduct scientifically rigorous studies to validate the efficacy of cognitive intervention trials. Future studies will greatly benefit from including longitudinal imaging in their study design. Imaging can be used to demonstrate the efficacy and mechanisms by measuring brain changes over the intervention period. Imaging can also be used to determine biological and disease-related factors that may influence the treatment response, that is, the effect modifiers. Consideration of effect modifiers will allow us to measure the treatment response in biomarkers and cognition with greater sensitivity and also aid in designing trials that will lead to better patient outcomes.

20 Review Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. 2016

Shulman, Lisa M / Armstrong, Melissa / Ellis, Terry / Gruber-Baldini, Ann / Horak, Fay / Nieuwboer, Alice / Parashos, Sotirios / Post, Bart / Rogers, Mark / Siderowf, Andrew / Goetz, Christopher G / Schrag, Anette / Stebbins, Glenn T / Martinez-Martin, Pablo. ·Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA. lshulman@som.umaryland.edu. · Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA. · Department of Physical Therapy & Athletic Training, Boston University, Boston, Massachusetts, USA. · Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. · Department of Neurology, Oregon Health and Science University and Portland VA Medical System, Portland, Oregon, USA. · Department of Rehabilitation Science, KU Leuven-University of Leuven, Heverlee, Belgium. · Struthers Parkinson's Center, Golden Valley, Minnesota, USA. · Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands. · Department of Physical Therapy & Rehabilitation, University of Maryland School of Medicine, Baltimore, Maryland, USA. · Avid Radiopharmaceuticals, Philadelphia, PA, USA. · Department of Neurology, Rush University Medical Center, Chicago, USA. · UCL Institute of Neurology, University College London, UK. · National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. ·Mov Disord · Pubmed #27193358.

ABSTRACT: INTRODUCTION: PD is associated with impairments that progress over time to disability. A large number of disability scales exist with little information on the best choice in PD. METHODS: Following methodology adopted by the International Parkinson and Movement Disorder Society Task Force, a review of disability scales used in PD was completed. Based on prespecified criteria, the review categorized scales into: "Recommended"; "Recommended with Further Validation in PD Required" when well-validated scales have not been specifically tested for clinimetric properties in PD; "Suggested"; and "Listed." RESULTS: Twenty-nine disability instruments were identified with nine scales fulfilling criteria for "Recommended" and 7 "Recommended with Further Validation in PD Required." Eight scales are "Suggested" and five scales are "Listed" for use in PD. The nine Recommended scales (Functional Status Questionnaire, Lawton-Brody Activities of Daily Living, Nottingham Activities of Daily Living, Schwab and England Activities of Daily Living, Self-Assessment PD Disability, Short Parkinson's Evaluation Scale/Scales for Outcomes in PD, Unified PD Rating Scale-II: Activities of Daily Living, Movement Disorders Society UPDRS Motor Experiences of Daily Living, PROMIS CONCLUSION: Many disability measures are available and recommended for application in PD. The Task Force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2016 International Parkinson and Movement Disorder Society.

21 Review Technology in Parkinson's disease: Challenges and opportunities. 2016

Espay, Alberto J / Bonato, Paolo / Nahab, Fatta B / Maetzler, Walter / Dean, John M / Klucken, Jochen / Eskofier, Bjoern M / Merola, Aristide / Horak, Fay / Lang, Anthony E / Reilmann, Ralf / Giuffrida, Joe / Nieuwboer, Alice / Horne, Malcolm / Little, Max A / Litvan, Irene / Simuni, Tanya / Dorsey, E Ray / Burack, Michelle A / Kubota, Ken / Kamondi, Anita / Godinho, Catarina / Daneault, Jean-Francois / Mitsi, Georgia / Krinke, Lothar / Hausdorff, Jeffery M / Bloem, Bastiaan R / Papapetropoulos, Spyros / Anonymous1111027. ·James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio, USA. alberto.espay@uc.edu. · Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA. · Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. · Department of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tuebingen, Tübingen, Germany. · DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany. · Davis Phinney Foundation for Parkinson's, Boulder, Colorado, USA. · Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. · Digital Sports Group, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. · Department of Neuroscience "Rita Levi Montalcini", Città della salute e della scienza di Torino, Torino, Italy. · Department of Neurology, Oregon Health & Science University, Portland VA Medical System, Portland, Oregon. · APDM, Inc., Portland, Oregon, USA. · Morton and Gloria Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Canada. · George-Huntington-Institute, Muenster, Germany. · Department of Radiology, University of Muenster, Muenster, Germany. · Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. · Great Lakes NeuroTechnologies, Cleveland, Ohio, USA. · Neuromotor Rehabilitation Research Group, Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium. · Global Kinetics Corporation & Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia. · Department of Mathematics, Aston University, Birmingham, UK. · Media Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. · Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. · Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA. · Michael J Fox Foundation for Parkinson's Research, New York City, New York, USA. · Department of Neurology, National Institute of Clinical Neurosciences, Budapest, Hungary. · Center of Interdisciplinary Research Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, Monte de Caparica, Portugal. · Apptomics LLC, Wellesley, Massachusetts, USA. · Medtronic Neuromodulation, Minneapolis, Minnesota, USA. · Sackler School of Medicine, Tel Aviv University and Center for the Study of Movement, Cognition, and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. · Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, the Netherlands. · Massachusetts General Hospital, Boston, Massachusetts, USA. ·Mov Disord · Pubmed #27125836.

ABSTRACT: The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include noncompatible technology platforms, the need for wide-scale and long-term deployment of sensor technology (among vulnerable elderly patients in particular), and the gap between the "big data" acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms that enable multichannel data capture sensitive to the broad range of motor and nonmotor problems that characterize PD and are adaptable into self-adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed-loop therapeutic systems with high patient adherence that also serve to (1) encourage the adoption of clinico-pathophysiologic phenotyping and early detection of critical disease milestones, (2) enhance the tailoring of symptomatic therapy, (3) improve subgroup targeting of patients for future testing of disease-modifying treatments, and (4) identify objective biomarkers to improve the longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD. © 2016 International Parkinson and Movement Disorder Society.

22 Review Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. 2016

Sechi, GianPietro / Sechi, Elia / Fois, Chiara / Kumar, Neeraj. ·G.P. Sechi, E. Sechi, and C. Fois are with the Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. N. Kumar is with the Mayo Clinic, Rochester, Minnesota, USA. gpsechi@uniss.it. · G.P. Sechi, E. Sechi, and C. Fois are with the Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. N. Kumar is with the Mayo Clinic, Rochester, Minnesota, USA. ·Nutr Rev · Pubmed #27034475.

ABSTRACT: B vitamin deficiency is a leading cause of neurological impairment and disability throughout the world. Multiple B vitamin deficiencies often coexist, and thus an understanding of the complex relationships between the different biochemical pathways regulated in the brain by these vitamins may facilitate prompter diagnosis and improved treatment. Particular populations at risk for multiple B vitamin deficiencies include the elderly, people with alcoholism, patients with heart failure, patients with recent obesity surgery, and vegetarians/vegans. Recently, new clinical settings that predispose individuals to B vitamin deficiency have been highlighted. Moreover, other data indicate a possible pathogenetic role of subclinical chronic B vitamin deficiency in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. In light of these findings, this review examines the clinical manifestations of B vitamin deficiency and the effect of B vitamin deficiency on the adult nervous system. The interrelationships of multiple B vitamin deficiencies are emphasized, along with the clinical phenotypes related to B vitamin deficiencies. Recent advances in the clinical determinants and diagnostic clues of B vitamin deficiency, as well as the suggested therapies for B vitamin disorders, are described.

23 Review A Review of the Association Between Parkinson Disease and Malignant Melanoma. 2016

Disse, Max / Reich, Hilary / Lee, Peter K / Schram, Sarah S. ·*University of Minnesota Medical School, Minneapolis, Minnesota; †Department of Dermatology, University of Minnesota Medical Center, Minneapolis, Minnesota. ·Dermatol Surg · Pubmed #26771684.

ABSTRACT: BACKGROUND: An association between melanoma and Parkinson disease (PD) has been hinted at in the neurology and oncology literature since the 1970s after the initiation of levodopa (L-DOPA) therapy for PD. Given that L-DOPA is a substrate in melanin synthesis, there existed a concern that this therapy might cause melanoma. OBJECTIVE: The objective was to research possible etiological links to explain the connection between PD and melanoma. METHODS: A PubMed and Google Scholar literature search was performed using access provided by the University of Minnesota biomedical library. RESULTS: Patients with PD have an overall decreased risk of cancer diagnoses. However, breast cancer and melanoma have an uncharacteristically high rate of co-occurrence with PD. Family history of melanoma and lighter hair and skin color confer a higher risk of developing PD, and having a first-degree relative with either disease conveys a significantly increased risk of developing the other. Other possible connections that have been explored include pigmentation genes in neural-derived cells, pesticides, MC1R polymorphisms, and abnormal cellular autophagy. CONCLUSION: Although a link between PD and melanoma exists, the etiology of this link continues to be elusive. Both PD and melanoma are likely multifactorial diseases involving genetic and environmental risk factors.

24 Review Magnetic resonance imaging as a potential biomarker for Parkinson's disease. 2016

Tuite, Paul. ·Department of Neurology, University of Minnesota, Minneapolis, Minnesota. Electronic address: tuite002@umn.edu. ·Transl Res · Pubmed #26763585.

ABSTRACT: Although a magnetic resonance imaging (MRI) biomarker for Parkinson's disease (PD) remains an unfulfilled objective, there have been numerous developments in MRI methodology and some of these have shown promise for PD. With funding from the National Institutes of Health and the Michael J Fox Foundation there will be further validation of structural, diffusion-based, and iron-focused MRI methods as possible biomarkers for PD. In this review, these methods and other strategies such as neurochemical and metabolic MRI have been covered. One of the challenges in establishing a biomarker is in the selection of individuals as PD is a heterogeneous disease with varying clinical features, different etiologies, and a range of pathologic changes. Additionally, longitudinal studies are needed of individuals with clinically diagnosed PD and cohorts of individuals who are at great risk for developing PD to validate methods. Ultimately an MRI biomarker will be useful in the diagnosis of PD, predicting the course of PD, providing a means to track its course, and provide an approach to select and monitor treatments.

25 Review Lewy body dementias. 2015

Walker, Zuzana / Possin, Katherine L / Boeve, Bradley F / Aarsland, Dag. ·Division of Psychiatry, University College London, London, UK; North Essex Partnership University NHS Foundation Trust, Epping, UK. Electronic address: z.walker@ucl.ac.uk. · University of California, San Francisco School of Medicine, San Francisco, CA, USA. · Division of Behavioral Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Division of Movement Disorders, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Center for Sleep Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. · Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway; Department of Geriatric Psychiatry, Akershus University Hospital, Oslo, Norway; Department of Neurobiology, Care Sciences and Society, Division of Alzheimer's Disease Research Centre, Karolinska Institute, Stockholm, Sweden. ·Lancet · Pubmed #26595642.

ABSTRACT: The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.

Next